Shehnaaz Suliman
Director at Ultragenyx Pharmaceutical Inc. (RARE); Director at 10x Genomics, Inc. (TXG)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $936K
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 24SEC | TXG10x Genomics, Inc. | Sell Plan | 29229,223 held (−1%) | $78.20 | $23K | +3.1% |
| Sep 24SEC | TXG10x Genomics, Inc. | Sell Plan | 61428,609 held (−2%) | $79.51 | $49K | +1.4% |
| Sep 24SEC | TXG10x Genomics, Inc. | Sell Plan | 1,32527,284 held (−5%) | $80.82 | $107K | -0.2% |
| Sep 24SEC | TXG10x Genomics, Inc. | Sell Plan | 2,27025,014 held (−8%) | $81.67 | $185K | -1.2% |
| Sep 24SEC | TXG10x Genomics, Inc. | Sell Plan | 1,22223,792 held (−5%) | $82.28 | $101K | -2.0% |
| Aug 26SEC | TXG10x Genomics, Inc. | Sell Plan | 56131,161 held (−2%) | $62.73 | $35K | +28.6% |
| Aug 26SEC | TXG10x Genomics, Inc. | Sell Plan | 1,64629,515 held (−5%) | $63.97 | $105K | +26.1% |
| Jun 18SEC | TXG10x Genomics, Inc. | Sell Plan | 5,35932,086 held (−14%) | $32.59 | $175K | +147.5% |
| Jun 18SEC | TXG10x Genomics, Inc. | Sell Plan | 36431,722 held (−1%) | $33.27 | $12K | +142.4% |
| May 18SEC | RAREUltragenyx Pharmaceutical Inc. | Sell Plan | 5,74027,951 held (−17%) | $25.12 | $144K | -38.4% |
- Sell
Director Shehnaaz Suliman sold $23K of TXG at $78.20 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Shehnaaz Suliman sold $49K of TXG at $79.51 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Shehnaaz Suliman sold $107K of TXG at $80.82 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Shehnaaz Suliman sold $185K of TXG at $81.67 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Shehnaaz Suliman sold $101K of TXG at $82.28 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Shehnaaz Suliman sold $35K of TXG at $62.73 — pre-scheduled 10b5-1 plan sale.